Compare · BTI vs PXMD
BTI vs PXMD
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI carries a market cap of $129.12B.
- BTI has hit the wire 6 times in the past 4 weeks while PXMD has been quiet.
- BTI has more recent analyst coverage (15 ratings vs 0 for PXMD).
- Company
- British American Tobacco Industries p.l.c.
- PaxMedica Inc.
- Price
- -
- -
- Market cap
- $129.12B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- 2022
- News (4w)
- 6
- 0
- Recent ratings
- 15
- 0
BTI
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- BTIG Research initiated coverage on British American Tobacco
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection